

PRODUCT INFORMATION



Ximelagatran

Item No. 16862

CAS Registry No.: 192939-46-1
Formal Name: N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidiny]-2-oxoethyl]-glycine, ethyl ester

Synonyms: Exanta, H 376/95

MF: C₂₄H₃₅N₅O₅

FW: 473.6


Purity: ≥98%

UV/Vis.: λ_{max}: 265 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ximelagatran is supplied as a crystalline solid. A stock solution may be made by dissolving the ximelagatran in the solvent of choice, which should be purged with an inert gas. Ximelagatran is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of ximelagatran in ethanol and DMF is approximately 1 mg/ml and approximately 5 mg/ml in DMSO.

Ximelagatran is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ximelagatran should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Ximelagatran has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Ximelagatran is an ester prodrug of melagatran, a potent, direct, and reversible thrombin inhibitor ($K_i = 1.2$ nM).^{1,2} While melagatran has poor oral bioavailability, ximelagatran displays good bioavailability resulting, in part, from rapid absorption at the gastrointestinal tract, as well as rapid onset of action.² Ximelagatran is converted to melagatran by reduction and hydrolysis at the liver and other tissues.^{1,2} It is used as an anticoagulant in a variety of situations, including thromboembolic disorders, stroke prevention in atrial fibrillation, and therapy in vein thrombosis.^{2,3}

References

1. Clement, B. and Lopian, K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. *Drug Metab. Dispos.* **31(5)**, 645-651 (2003).
2. Ho, S.J. and Brighton, T.A. Ximelagatran: Direct thrombin inhibitor. *Vasc. Health Risk Manag.* **2(1)**, 49-58 (2006).
3. Ufer, M. Comparative pharmacokinetics of vitamin K antagonists warfarin, phenprocoumon and acenocoumarol. *Clin. Pharmacokinet.* **44(12)**, 1227-1246 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM